PSNL News and Press, Personalis Inc. From 11/12/21

Personalis recognized in inaugural roundup for proven track record of management excellence Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has been named to Inc. ’s inaugural 2021 Best-Led Companies list ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium. ...

Personalis, Inc. (PSNL) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Neel Ram...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Reported quarterly revenue of $22.3 million in the thir...

Personalis (NASDAQ:PSNL) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.42 and the consensus Revenue Estimate is $22.24M (+12.3% Y/Y). Over the last 3 months, EPS estimates have seen 6 upward revisions and 2 downwa...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how the...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy ™ . The first patent, US Patent No. 11,142,802, entitle...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the publication of its study “ Precision neoantigen discovery using large-scale immunopeptidomes and composite modeling of MHC peptide presentation ,” in the Immunopeptidomics ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021. In conjunction with the release, the company will host a conference call and webcast...